APASL consensus statements and management algorithms for hepatitis C virus infection.
about
Hepatitis C genotype 6: A concise review and response-guided therapy proposalHepatitis C virus protease inhibitor-resistance mutations: our experience and reviewConceptual framework for outcomes research studies of hepatitis C: an analytical reviewNoninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining IssuesControversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinomaFactors associated with the response to interferon-based antiviral therapies for chronic hepatitis CNew treatments for genotype 1 chronic hepatitis C - focus on simeprevirA 2015 roadmap for the management of hepatitis C virus infections in AsiaHepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infectionChanging Epidemiology of Hepatitis C Virus Genotype among Patients with Human Immunodeficiency Virus/Hepatitis C Virus Co-Infection in ChinaPersonalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized StudyAPASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataPlatelet count and sustained virological response in hepatitis C treatment.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients.Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic responseDisease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.Modulation of TLR 3, 7 and 8 expressions in HCV genotype 3 infected individuals: potential correlations of pathogenesis and spontaneous clearance.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled TrialsHepatitis C and kidney disease: An overview and approach to management.Viral hepatitis and human immunodeficiency virus co-infections in AsiaComparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care.Characterization of the Interleukin-28B Gene rs12979860 C/T Polymorphism in Turkish Chronic Hepatitis C Patients and Healthy Individuals.Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey.Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6.Current management of patients with hepatocellular carcinoma.Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.Response Guided Interferon Therapy for Genotype 3 of Chronic Hepatitis C: Compliance and Outcome.Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirinPeginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.
P2860
Q22305417-36B048EB-65E1-420F-907A-C24D8A2F9859Q24628717-92D93D50-61FA-4053-9118-D2EF220ACA03Q26745582-8E3C9447-C99F-40C0-B2B7-2320C8693ED4Q26770020-76F31299-81D8-456C-9466-AC11DFC6042DQ26772324-A320AB6F-A861-41C1-831B-709AE0888AF4Q26825715-B6C31EA8-9CC4-4507-A240-8C20B2D3461DQ26853138-08B49002-A5C9-46FA-B27E-D1D1E51E0315Q28088762-AD0103A0-3110-4537-8F7F-44C124126482Q28537754-77AC32E0-3793-4BC2-9B66-48DB485A03DDQ28553922-548D3062-DB3B-4ED0-9E4B-05F3F9A1D54CQ28608449-F83A9D31-BF95-4EC0-B011-6E094347A6CAQ30250088-7DFDED7D-B9EF-4D5B-A296-D80A536DA80DQ30417045-097DCD65-F2DF-4755-82F0-9C0D05491F69Q31042796-2BD7FF1A-7F7C-4639-BE3C-87E36027D890Q33407719-61C4C4B0-3039-4B4D-A8D7-913A9073BFD2Q33559298-5AB2AB9C-1983-4B46-86C1-40D21AB9BA44Q33734636-68BA33E2-CDCA-45A0-A2A0-B12E505F4BC5Q33769085-AE6A988B-3169-47D5-8A66-8BDB47E1720AQ33845581-F32E5EC2-CA5E-47B8-A27E-9C32924BF5F2Q33948241-5254F19C-1E22-43FA-ACF6-8A95B71E70C6Q34003232-B6C76FD2-9FF4-4DAA-8E4A-254ABA423381Q34411617-CB2FBFAE-914F-4A0E-A572-0DDC0214E4DBQ34634369-6B711092-AC6A-4634-BC8F-463883B6B758Q34714220-0779B807-11E8-4B70-9AA6-B1AE4EC54845Q34966853-86BDA45B-72BA-4299-A462-17750C579E54Q35567832-9182CA25-3915-46C4-8D37-E311B092B2BCQ35602958-2A99BE87-0B34-4237-AB89-9769C78E8404Q35609162-1D1DAB97-806F-4344-AAFA-C1E6E61D39B4Q35835981-0D161379-7B06-4495-B4EB-08B509DE5597Q35885715-858EA916-F57C-487B-8266-5CB3B785D6AAQ35895363-7A7D4765-142E-4FC8-80F6-87B5FDBFD05FQ35905985-BE3C4953-A4D9-45EB-A46D-5141FC40D844Q35947900-840034EA-F8F8-4590-B2D6-F8F0BD1B6CB8Q36009124-7F72A88C-6DC9-413B-8553-57F225046E89Q36073283-65F27AFA-BC05-419D-BF0F-DF6419E78173Q36095525-926B7F2C-FDBB-4486-BE7A-111FB0B711A6Q36111011-6D0D8927-40B6-4ADF-92CB-51A18926F1DFQ36246785-BE2A5B87-1700-4F9D-A09C-69BAAA4B1EF6Q36488315-B88B7528-F1EB-4C8B-B391-75BE5BE22592Q36501509-28F62C81-177F-45BF-BBD5-55B20E65E957
P2860
APASL consensus statements and management algorithms for hepatitis C virus infection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
APASL consensus statements and management algorithms for hepatitis C virus infection.
@en
type
label
APASL consensus statements and management algorithms for hepatitis C virus infection.
@en
prefLabel
APASL consensus statements and management algorithms for hepatitis C virus infection.
@en
P2093
P2860
P1476
APASL consensus statements and management algorithms for hepatitis C virus infection
@en
P2093
Anuchit Chutaputti
Geoffrey W McCaughan
Jose Sollano
Masao Omata
Ming-Lung Yu
Osamu Yokosuka
Saeed S Hamid
Seng-Gee Lim
Shiv Kumar Sarin
P2860
P2888
P304
P356
10.1007/S12072-012-9342-Y
P577
2012-03-01T00:00:00Z
P5875
P6179
1038911223